Clinical Trial: Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title:
Brief Summary: The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.
Detailed Summary:
Sponsor: University Hospital, Geneva
Current Primary Outcome: Platelet reactivity assessed by light transmittance aggregometry (LTA) after ex-vivo normal platelet addition [ Time Frame: within the first 6-24 hours after antiplatelet drug loading dose ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: University Hospital, Geneva
Dates:
Date Received: April 22, 2013
Date Started: September 2011
Date Completion:
Last Updated: August 18, 2014
Last Verified: August 2014